The difference is in the dosing
So I'm sorry, I'll let you ask, ask me the question
Description SLU-PP-332 is a potent, selective pan-agonist of the estrogen-related receptor (ERR) family ERR, ERR, and ERR developed at Saint Louis University
Both compounds share GLP-1 and GIP receptor activity, but retatrutide adds glucagon activation
In those cases, the data may still be scientifically useful, but it should not be described as exclusively NNMT-mediated without additional evidence
Yes, when administered under medical supervision, both treatments are considered very safe and well-tolerated